{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:33:37Z","timestamp":1789187617610,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1136\/ijgc-2021-002467","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T11:30:27Z","timestamp":1621510227000},"page":"1037-1044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Metronomic oral cyclophosphamide in relapsed ovarian cancer"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6486-6319","authenticated-orcid":false,"given":"Pavlina","family":"Spiliopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Hinsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain A","family":"McNeish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Roxburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ros","family":"Glasspool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2021-002467_bb0010","unstructured":"Cancer Research UK . Ovarian cancer 2019. Available: https:\/\/www.cancerresearchuk.org\/about-cancer\/ovarian-cancer\/survival"},{"key":"10.1136\/ijgc-2021-002467_bb0015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1586\/era.09.165","article-title":"Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs","volume":"10","author":"Harter","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1136\/ijgc-2021-002467_bb0020","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2165\/11591720-000000000-00000","article-title":"Management strategies for recurrent platinum-resistant ovarian cancer","volume":"71","author":"Naumann","year":"2011","journal-title":"Drugs"},{"key":"10.1136\/ijgc-2021-002467_bb0025","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002467_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002467_bb0035","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002467_bb0040","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002467_bb0045","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s10147-010-0094-1","article-title":"Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer","volume":"15","author":"Watanabe","year":"2010","journal-title":"Int J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002467_bb0050","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-947","article-title":"Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study","volume":"14","author":"Ferrandina","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2021-002467_bb0055","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/ajco.12074","article-title":"Oral cyclophosphamide in recurrent ovarian cancer","volume":"12","author":"Handolias","year":"2016","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002467_bb0060","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2021-002467_bb0065","author":"GCIG","year":"2005","journal-title":"CA 125 definitions agreed by GCIG November 2005"},{"key":"10.1136\/ijgc-2021-002467_bb0070","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2021-002467_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4061\/2010\/543531","article-title":"DNA damage induced by alkylating agents and repair pathways","volume":"2010","author":"Kondo","year":"2010","journal-title":"J Nucleic Acids"},{"key":"10.1136\/ijgc-2021-002467_bb0080","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ygyno.2020.09.048","article-title":"A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer","volume":"159","author":"Hall","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002467_bb0085","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/2326-6066.CIR-15-0044","article-title":"CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer","volume":"3","author":"Higuchi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1136\/ijgc-2021-002467_bb0090","unstructured":"Y Motoyoshi , KKaminoda, OSaitoh, et al . Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep.10.3892\/or.16.1.141"},{"key":"10.1136\/ijgc-2021-002467_bb0095","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1136\/ijgc-2021-002467_bb0100","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1158\/0008-5472.CAN-08-4102","article-title":"Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model","volume":"69","author":"Wada","year":"2009","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2021-002467_bb0105","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.4161\/onci.20684","article-title":"Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice","volume":"1","author":"Malvicini","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1136\/ijgc-2021-002467_bb0110","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/mt.2011.113","article-title":"Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus","volume":"19","author":"Cerullo","year":"2011","journal-title":"Mol Ther"},{"key":"10.1136\/ijgc-2021-002467_bb0115","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41588-020-0630-5","article-title":"Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy","volume":"52","author":"Jim\u00e9nez-S\u00e1nchez","year":"2020","journal-title":"Nat Genet"},{"key":"10.1136\/ijgc-2021-002467_bb0120","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1158\/1078-0432.CCR-15-2657","article-title":"Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma","volume":"22","author":"B\u00f6hm","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2021-002467_bb0125","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.055","article-title":"BAROCCO: a randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC)","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2021-002467_bb0130","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ygyno.2018.11.030","article-title":"Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors","volume":"152","author":"Stanley","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002467_bb0135","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3440-0","article-title":"The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole","volume":"17","author":"George","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2021-002467_bb0140","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.106","article-title":"TOPACIO\/Keynote-162 (NCT02657889): a phase 1\/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)\u2014results from ROC cohort","volume":"36","author":"Konstantinopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002467_bb0145","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2013.24.3.209","article-title":"Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer","volume":"24","author":"Pujade-Lauraine","year":"2013","journal-title":"J Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002467_bb0150","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/annonc\/mdw238","article-title":"Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the aurelia trial","volume":"27","author":"Lindemann","year":"2016","journal-title":"Ann Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24005255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24005255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2021-002467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:38:41Z","timestamp":1753223921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24005255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1048891X24005255"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2021-002467","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metronomic oral cyclophosphamide in relapsed ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2021-002467","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}